全文获取类型
收费全文 | 2010篇 |
免费 | 131篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 59篇 |
妇产科学 | 21篇 |
基础医学 | 255篇 |
口腔科学 | 36篇 |
临床医学 | 152篇 |
内科学 | 609篇 |
皮肤病学 | 32篇 |
神经病学 | 112篇 |
特种医学 | 90篇 |
外科学 | 367篇 |
综合类 | 9篇 |
预防医学 | 106篇 |
眼科学 | 26篇 |
药学 | 86篇 |
中国医学 | 6篇 |
肿瘤学 | 189篇 |
出版年
2024年 | 4篇 |
2023年 | 29篇 |
2022年 | 72篇 |
2021年 | 125篇 |
2020年 | 54篇 |
2019年 | 73篇 |
2018年 | 102篇 |
2017年 | 76篇 |
2016年 | 66篇 |
2015年 | 75篇 |
2014年 | 86篇 |
2013年 | 98篇 |
2012年 | 143篇 |
2011年 | 147篇 |
2010年 | 107篇 |
2009年 | 75篇 |
2008年 | 128篇 |
2007年 | 126篇 |
2006年 | 100篇 |
2005年 | 90篇 |
2004年 | 78篇 |
2003年 | 77篇 |
2002年 | 81篇 |
2001年 | 21篇 |
2000年 | 17篇 |
1999年 | 20篇 |
1998年 | 15篇 |
1997年 | 13篇 |
1996年 | 6篇 |
1995年 | 6篇 |
1994年 | 4篇 |
1993年 | 3篇 |
1992年 | 7篇 |
1991年 | 9篇 |
1990年 | 1篇 |
1989年 | 5篇 |
1988年 | 2篇 |
1987年 | 4篇 |
1986年 | 7篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1975年 | 1篇 |
1969年 | 2篇 |
1968年 | 2篇 |
1966年 | 1篇 |
1963年 | 1篇 |
1957年 | 1篇 |
排序方式: 共有2164条查询结果,搜索用时 31 毫秒
91.
Takahiro Ando Hidenori Kage Yoko Matsumoto Koichi Zokumasu Takuma Yotsumoto Keita Maemura Yosuke Amano Kousuke Watanabe Jun Nakajima Takahide Nagase Daiya Takai 《Cancer science》2020,111(1):200-208
Integrins are transmembrane proteins that mediate cell adhesion to the extracellular matrix. Integrin α11 (ITGA11) is not expressed in normal alveolar epithelial cells and is a known receptor for collagen. While integrin α11β1 overexpression in the tumor stroma has been associated with tumor growth and metastatic potential of non–small cell lung cancer (NSCLC), little is known about the role of ITGA11 in tumor cells. Thus, we examined the RNA expression of ITGA11 by quantitative RT‐PCR in 80 samples collected from NSCLC patients who had undergone surgical resection and analyzed the clinical outcomes. We found that high expression of ITGA11 was associated with lower recurrence‐free survival in all NSCLC patients (P = 0.043) and in stage I NSCLC patients (P = 0.049). These results were consistent with in silico analyses of the Cancer Genome Atlas database. We also analyzed cell proliferation, migration and invasion capacity in lung cancer cell lines after overexpression of ITGA11. Overexpression of ITGA11 in lung cancer cell lines had little effect on cell proliferation but resulted in increased migration and invasion capacity. Our findings suggest that ITGA11 plays a significant role in cancer migration and invasion, leading to higher recurrence. ITGA11 expression may be a predictor of poor prognosis in patients with surgically resected NSCLC. 相似文献
92.
93.
Mory Keita Mahamoud Sama Cherif Billy Sivahera Samuel T. Boland Freddy Banza-Mutoka Mamadou Kourouma Alseny Modet Camara Youssouf Sidibe Jean Paul Kimenyi Lamine Diassy Angelo Loua Ibrahima Sory Fofana Youba Kandako Dobo Onivogui Enogo Koivogui Tamba Jacques Millimono Fode Diakite Mamadou Balde Bienvenu Houndjo Ngoy Nsenga Ambrose Talisuna Alexandre Delamou Olivia Keiser Georges Alfred Ki-Zerbo Abdou Salam Gueye 《The American journal of tropical medicine and hygiene》2022,106(4):1094
94.
Kimiaki Takagi Makoto Kawase Daiki Kato Kota Kawase Manabu Takai Koji Iinuma Keita Nakane Noriyasu Hagiwara Toru Yamada Masayuki Tomioka Takuya Koie 《Current oncology (Toronto, Ont.)》2022,29(4):2864
Recently, cytoreductive prostatectomy for metastatic prostate cancer (mPCa) has been associated with improved oncological outcomes. This study was aimed at evaluating whether robot-assisted radical prostatectomy (RARP) as a form of cytoreductive prostatectomy can improve oncological outcomes in patients with mPCa. We conducted a retrospective study of twelve patients with mPCa who had undergone neoadjuvant therapy followed by RARP. The endpoints were biochemical recurrence-free survival, treatment-free survival, and de novo metastasis-free survival. At the end of the follow-up period, none of the enrolled patients had died from PCa. The 1- and 2-year biochemical recurrence-free survival rates were 83.3% and 66.7%, respectively, and treatment-free survival rates were 75.0% and 56.3%, respectively. One patient developed de novo bone metastases 6.4 months postoperatively, and castration-resistant prostate cancer 8.9 months postoperatively. After RARP, the median duration of recovery of urinary continence was 5.2 months. One patient had severe incontinence (>2 pads/day) 24 months postoperatively. RARP may be a treatment option in patients with mPCa who have achieved a serum prostate-specific antigen level < 0.2 ng/mL, and present without new lesions on imaging. 相似文献
95.
Srdan Verstovsek Alessandro M. Vannucchi Martin Griesshammer Tamas Masszi Simon Durrant Francesco Passamonti Claire N. Harrison Fabrizio Pane Pierre Zachee Keita Kirito Carlos Besses Masayuki Hino Beatriz Moiraghi Carole B. Miller Mario Cazzola Vittorio Rosti Igor Blau Ruben Mesa Mark M. Jones Huiling Zhen Jingjin Li Nathalie Francillard Dany Habr Jean-Jacques Kiladjian 《Haematologica》2016,101(7):821-829
RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea-resistant or intolerant patients with polycythemia vera. This preplanned analysis occurred when all patients completed the Week 80 visit or discontinued. Objectives included evaluating the durability of the primary response (Week 32 phlebotomy-independent hematocrit control plus ≥35% spleen volume reduction), its components, and that of complete hematologic remission; and long-term safety. Median exposure was 111 weeks; 91/110 (82.7%) patients randomized to ruxolitinib remained on treatment. No patients continued best available therapy (98/112 [87.5%] crossed over to ruxolitinib, most at/soon after Week 32). At Week 32, primary response was achieved by 22.7% vs. 0.9% of patients randomized to ruxolitinib and best available therapy, respectively (hematocrit control, 60.0% vs. 18.8%; spleen response, 40.0% vs. 0.9%). The probability of maintaining primary and hematocrit responses for ≥80 weeks was 92% and 89%, respectively; 43/44 spleen responses were maintained until Week 80. Complete hematologic remission at Week 32 was achieved in 23.6% of ruxolitinib-randomized patients; the probability of maintaining complete hematologic remission for ≥80 weeks was 69%. Among ruxolitinib crossover patients, 79.2% were not phlebotomized, and 18.8% achieved a ≥35% reduction from baseline in spleen volume after 32 weeks of treatment. New or worsening hematologic laboratory abnormalities in ruxolitinib-treated patients were primarily grade 1/2 decreases in hemoglobin, lymphocytes, and platelets. The thromboembolic event rate per 100 patient-years was 1.8 with randomized ruxolitinib treatment vs. 8.2 with best available therapy. These data support ruxolitinib as an effective long-term treatment option for hydroxyurea-resistant or intolerant patients with polycythemia vera. This trial was registered at clinicaltrials.gov identifier: 01243944. 相似文献
96.
Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos)
下载免费PDF全文
![点击此处可从《Journal of hepato-biliary-pancreatic sciences》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Seiki Kiriyama Kazuto Kozaka Tadahiro Takada Steven M. Strasberg Henry A. Pitt Toshifumi Gabata Jiro Hata Kui‐Hin Liau Fumihiko Miura Akihiko Horiguchi Keng‐Hao Liu Cheng‐Hsi Su Keita Wada Palepu Jagannath Takao Itoi Dirk J. Gouma Yasuhisa Mori Shuntaro Mukai Mariano Eduardo Giménez Wayne Shih‐Wei Huang Myung‐Hwan Kim Kohji Okamoto Giulio Belli Christos Dervenis Angus C. W. Chan Wan Yee Lau Itaru Endo Harumi Gomi Masahiro Yoshida Toshihiko Mayumi Todd H. Baron Eduardo de Santibañes Anthony Yuen Bun Teoh Tsann‐Long Hwang Chen‐Guo Ker Miin‐Fu Chen Ho‐Seong Han Yoo‐Seok Yoon In‐Seok Choi Dong‐Sup Yoon Ryota Higuchi Seigo Kitano Masafumi Inomata Daniel J. Deziel Eduard Jonas Koichi Hirata Yoshinobu Sumiyama Kazuo Inui Masakazu Yamamoto 《Journal of hepato-biliary-pancreatic sciences》2018,25(1):17-30
Although the diagnostic and severity grading criteria on the 2013 Tokyo Guidelines (TG13) are used worldwide as the primary standard for management of acute cholangitis (AC), they need to be validated through implementation and assessment in actual clinical practice. Here, we conduct a systematic review of the literature to validate the TG13 diagnostic and severity grading criteria for AC and propose TG18 criteria. While there is little evidence evaluating the TG13 criteria, they were validated through a large‐scale case series study in Japan and Taiwan. Analyzing big data from this study confirmed that the diagnostic rate of AC based on the TG13 diagnostic criteria was higher than that based on the TG07 criteria, and that 30‐day mortality in patients with a higher severity based on the TG13 severity grading criteria was significantly higher. Furthermore, a comparison of patients treated with early or urgent biliary drainage versus patients not treated this way showed no difference in 30‐day mortality among patients with Grade I or Grade III AC, but significantly lower 30‐day mortality in patients with Grade II AC who were treated with early or urgent biliary drainage. This suggests that the TG13 severity grading criteria can be used to identify Grade II patients whose prognoses may be improved through biliary drainage. The TG13 severity grading criteria may therefore be useful as an indicator for biliary drainage as well as a predictive factor when assessing the patient's prognosis. The TG13 diagnostic and severity grading criteria for AC can provide results quickly, are minimally invasive for the patients, and are inexpensive. We recommend that the TG13 criteria be adopted in the TG18 guidelines and used as standard practice in the clinical setting. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content_id=47 . Related clinical questions and references are also included. 相似文献
97.
Indications and techniques of biliary drainage for acute cholangitis in updated Tokyo Guidelines 2018
下载免费PDF全文
![点击此处可从《Journal of hepato-biliary-pancreatic sciences》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Shuntaro Mukai Takao Itoi Todd H. Baron Tadahiro Takada Steven M. Strasberg Henry A. Pitt Tomohiko Ukai Satoru Shikata Anthony Yuen Bun Teoh Myung‐Hwan Kim Seiki Kiriyama Yasuhisa Mori Fumihiko Miura Miin‐Fu Chen Wan Yee Lau Keita Wada Avinash Nivritti Supe Mariano Eduardo Giménez Masahiro Yoshida Toshihiko Mayumi Koichi Hirata Yoshinobu Sumiyama Kazuo Inui Masakazu Yamamoto 《Journal of hepato-biliary-pancreatic sciences》2017,24(10):537-549
The Tokyo Guidelines 2013 (TG13) include new topics in the biliary drainage section. From these topics, we describe the indications and new techniques of biliary drainage for acute cholangitis with videos. Recently, many novel studies and case series have been published across the world, thus TG13 need to be updated regarding the indications and selection of biliary drainage based on published data. Herein, we describe the latest updated TG13 on biliary drainage in acute cholangitis with meta‐analysis. The present study showed that endoscopic transpapillary biliary drainage regardless of the use of nasobiliary drainage or biliary stenting, should be selected as the first‐line therapy for acute cholangitis. In acute cholangitis, endoscopic sphincterotomy (EST) is not routinely required for biliary drainage alone because of the concern of post‐EST bleeding. In case of concomitant bile duct stones, stone removal following EST at a single session may be considered in patients with mild or moderate acute cholangitis except in patients under anticoagulant therapy or with coagulopathy. We recommend the removal of difficult stones at two sessions after drainage in patients with a large stone or multiple stones. In patients with potential coagulopathy, endoscopic papillary dilation can be a better technique than EST for stone removal. Presently, balloon enteroscopy‐assisted endoscopic retrograde cholangiopancreatography (BE‐ERCP) is used as the first‐line therapy for biliary drainage in patients with surgically altered anatomy where BE‐ERCP expertise is present. However, the technical success rate is not always high. Thus, several studies have revealed that endoscopic ultrasonography‐guided biliary drainage (EUS‐BD) can be one of the second‐line therapies in failed BE‐ERCP as an alternative to percutaneous transhepatic biliary drainage where EUS‐BD expertise is present. 相似文献
98.
99.
Influence of preoperative anti‐cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: Project study by the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery
下载免费PDF全文
![点击此处可从《Journal of hepato-biliary-pancreatic sciences》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Fuyuhiko Motoi Michiaki Unno Hidenori Takahashi Takaho Okada Keita Wada Masayuki Sho Hiroaki Nagano Ippei Matsumoto Sohei Satoi Yoshiaki Murakami Masashi Kishiwada Goro Honda Hisafumi Kinoshita Hideo Baba Shoichi Hishinuma Minoru Kitago Hidehiro Tajima Hiroyuki Shinchi Hiroshi Takamori Tomoo Kosuge Hiroki Yamaue Tadahiro Takada 《Journal of hepato-biliary-pancreatic sciences》2014,21(2):148-158
100.